116 filings
Page 2 of 6
8-K
udhbz61fesrwippgu
29 Mar 23
CRISPR Therapeutics Announces Departure of Board Member
8:08am
8-K
oeiioapvxtdegj
27 Mar 23
Entry into a Material Definitive Agreement
8:08am
8-K
f5ontjelekeffrw
14 Mar 23
CRISPR Therapeutics Announces Transition of Chief Financial Officer
8:15am
8-K
0mnhnyomlp9ag
21 Feb 23
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
4:06pm
8-K
uc6wdcpwbdq9jwo5vf8k
1 Nov 22
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
4:05pm
8-K
wz83r5bh9f 1w
27 Oct 22
CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer
8:36am
8-K
u5edlb3x
27 Sep 22
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
7:48am
8-K
grba7h3t1xqh7
8 Aug 22
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
8:05am
8-K
werx972mjkc6nk6z
21 Jun 22
Other Events
5:05pm
8-K
tjdyi3vo3fp7wh3rzvdd
13 Jun 22
Departure of Directors or Certain Officers
4:58pm
8-K
96i6eslbtx020nq6i
13 Jun 22
Regulation FD Disclosure
8:02am
8-K
sm5al9cwa7 68bzfn0
16 May 22
CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer
4:14pm
8-K
fdwd i1nuprgo9
12 May 22
Regulation FD Disclosure
4:05pm
8-K
btss 9pp6s
9 May 22
Results of Operations and Financial Condition
4:06pm
8-K
6r9d8k7rn6h38r04w
15 Feb 22
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
4:05pm
8-K
v4pomqlhgwlel
20 Dec 21
Departure of Directors or Certain Officers
8:00am
8-K
jq9qmz3
22 Nov 21
Regulation FD Disclosure
8:42am
8-K
xyp75x9jyjzyvi97
3 Nov 21
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
4:07pm
8-K
pe2kaar4
14 Oct 21
CRISPR Therapeutics Announces Transition of Chief Financial Officer
7:15am
8-K
r0ud5s
12 Oct 21
CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed
4:46pm